Last updated: June 18, 2026
What is the case 1:15-cv-01205 and how did Sanofi frame its patent claims?
Case: Sanofi v. First Time US Generics LLC
Docket: 1:15-cv-01205
Court: Federal district court (district not stated in the provided information)
Parties (as named): Sanofi (plaintiff/patent owner) vs. First Time US Generics LLC (defendant/ANDA filer)
Sanofi’s filing is consistent with Hatch-Waxman patent infringement litigation tied to an Abbreviated New Drug Application (ANDA) and associated “Orange Book” patents. In these cases, Sanofi typically asserts one or more Orange Book-listed patents (composition, formulation, method-of-use, and/or manufacturing) against the generic’s proposed product and seeks injunctive relief under 35 U.S.C. § 271(e)(2), plus damages for infringement.
Litigation objectives (typical for this posture):
- Obtain a court order that the asserted patents are infringed and not invalid.
- Block approval or delay final approval of the generic application via an injunction.
- Use the litigation to narrow or eliminate noninfringement/invalidity defenses tied to the ANDA’s proposed formulation and labeling.
What patents were asserted in Sanofi’s lawsuit against First Time US Generics?
No asserted patent numbers, Orange Book listings, claims, or claim charts are provided in the input. Without the specific patent IDs and the asserted claims, a complete and accurate infringement/validity analysis cannot be produced.
What defenses did First Time US Generics raise in 1:15-cv-01205?
No pleadings, invalidity theories, noninfringement arguments, or procedural posture details are provided in the input. Without access to the complaint, answer, claim construction orders, or summary judgment records, a complete and accurate defense analysis cannot be produced.
What was the litigation timeline (filing, Markman, dispositive motions, trial, judgment)?
The input contains only the case caption identifier “1:15-cv-01205” and the parties. No docket dates, Markman schedule, motion outcomes, settlement dates, or judgment entries are included.
A timeline is not reproducible from the provided information.
What did the court decide: infringement, invalidity, or settlement?
No court disposition (dismissal, summary judgment, claim construction rulings, final judgment), no infringement/invalidity findings, and no settlement entry are provided in the input.
Did the case involve Paragraph IV (ANDA) and what does that imply for exclusivity and launch?
The presence of a branded-versus-ANDA litigation caption strongly suggests a Paragraph IV posture, but the record is not provided. A definitive statement about Paragraph IV status, Orange Book-listed patents, and the statutory consequences (180-day exclusivity, trigger events, and forfeiture) cannot be produced without the specific patent and notice/ANDA details.
How strong is Sanofi’s patent estate in this dispute?
Patent-strength scoring requires the asserted patent families, claim scope, prosecution history, litigation history, and claim construction outcomes. None are included in the provided information.
How does this case compare with other Sanofi ANDA patent challenges?
A comparison requires: the specific drug, active ingredient, asserted patents, and outcome. These details are not included in the input. Without them, any comparison would not be anchored to the actual estate and results.
What is the regulatory impact for First Time US Generics: injunction risk, FDA timing, and potential “design-around”?
Regulatory impact depends on:
- whether the generic product was enjoined,
- the specific listed patents at issue,
- whether any patents were found not infringed or invalid,
- whether any noninfringement arguments resulted in claim redesign.
None of those details are in the provided information.
Settlement terms: did Sanofi and First Time US Generics reach a deal?
No settlement agreement, terms, dates, or court-entered consent judgment are provided. Without those, a settlement analysis cannot be produced.
What manufacturing or formulation issues were litigated?
Litigation typically targets infringement through:
- ANDA formulation composition (excipients, salt form, polymorph),
- bioequivalence-relevant properties,
- method-of-use labeling changes.
No formulation, manufacturing, or label issues are included in the input.
Key Takeaways
- The provided information identifies the case by caption and docket number (Sanofi v. First Time US Generics LLC, 1:15-cv-01205), but it does not include the asserted patents, procedural posture, or disposition required to produce a complete litigation summary and analysis.
- A legally actionable infringement/validity analysis, timeline, and regulatory impact assessment cannot be generated from the supplied data.
FAQs
- What does “1:15-cv-01205” correspond to in Hatch-Waxman terms?
- Which Orange Book patents are typically asserted in Sanofi v. an ANDA filer like First Time US Generics?
- How do claim construction rulings usually affect Paragraph IV generic defenses in Sanofi-style patent estates?
- What are the most common settlement structures in ANDA patent litigations involving Sanofi?
- How does a finding of noninfringement versus invalidity change the FDA approval timeline?
References
No sources were provided in the input to cite.
